Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARBYCLOR vs ATACAND HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Treatment of hypertension to lower blood pressure; lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
Treatment of hypertension, for patients not adequately controlled on monotherapy.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan; azilsartan is metabolized primarily by CYP2C9. Chlorthalidone is minimally metabolized, with most of the dose excreted unchanged in urine.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Azilsartan: >99% bound to serum albumin; chlorthalidone: approximately 75% bound to albumin and lipoproteins
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Azilsartan: approximately 16 L (0.2 L/kg) indicating limited extravascular distribution; chlorthalidone: approximately 3-4 L/kg (extensive tissue binding, particularly to erythrocytes)
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Azilsartan medoxomil: absolute bioavailability approximately 60% (oral); chlorthalidone: approximately 65% (oral)
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
e GFR <30 m L/min/1.73m2: not recommended. No adjustment required for e GFR ≥30 m L/min/1.73m2.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): contraindicated. Child-Pugh Class C (severe): contraindicated.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
Not established; safety and efficacy in pediatric patients have not been studied.
Safety and efficacy not established in pediatric patients (<18 years).
Initiate with the lowest available dose (40 mg/12.5 mg) and titrate cautiously due to increased risk of hypotension and electrolyte disturbances.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
None
None.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause oligohydramnios, fetal renal dysfunction, and neonatal hypotension, hyperkalemia, and skull hypoplasia. Discontinue Edarbyclor as soon as possible when pregnancy is detected.,Hypotension: Correct volume- or salt-depleted patients prior to initiation; monitor for symptomatic hypotension.,Electrolyte disturbances: Chlorthalidone may cause hypokalemia, hyponatremia, and hypomagnesemia. Monitor electrolytes periodically.,Renal function deterioration: Monitor renal function in patients with renal artery stenosis, severe heart failure, or volume depletion.,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant use of potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium.,Acute angle-closure glaucoma: Chlorthalidone, as a sulfonamide derivative, can cause idiosyncratic reaction leading to acute transient myopia and acute angle-closure glaucoma.,Exacerbation of systemic lupus erythematosus: Chlorthalidone may exacerbate or activate SLE.,Metabolic: Chlorthalidone may increase serum glucose, uric acid (precipitating gout), and decrease urinary calcium excretion.,Sulfonamide allergy: Chlorthalidone is a sulfonamide derivative; caution in patients with sulfonamide allergy.
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Anuria,Hypersensitivity to azilsartan medoxomil, chlorthalidone, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes mellitus
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, salt substitutes) in excess due to risk of hyperkalemia. Avoid excessive salt intake. Grapefruit juice may alter drug metabolism; limit or avoid consumption. Alcohol may potentiate hypotensive effects.
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the second and third trimesters. There is no known risk of major malformations with first trimester exposure, but data are limited. Second and third trimesters: Use is contraindicated due to fetal renal dysfunction, oligohydramnios, pulmonary hypoplasia, limb contractures, and neonatal anuria, hypotension, and death. Azilsartan medoxomil (ARB) and chlorthalidone (thiazide diuretic) both affect RAS and fetal hemodynamics.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
No data on azilsartan medoxomil or chlorthalidone presence in human milk, effects on the breastfed infant, or milk production. Chlorthalidone is present in breast milk at low levels; M/P ratio unknown. Due to potential for adverse effects in the nursing infant (e.g., hypotension, renal impairment), alternative agents are recommended.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
EDARBYCLOR is not recommended in pregnancy, especially during second and third trimesters; if exposure occurs, discontinue as soon as possible. No specific dose adjustment studied; however, pregnancy can increase volume of distribution and clearance of some antihypertensives, but no data for this combination. Use is contraindicated after first trimester.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil (an ARB) and chlorthalidone (a thiazide-like diuretic). Monitor renal function and electrolytes regularly due to risk of hypotension, hyperkalemia, and hyponatremia. Avoid use in patients with anuria or severe renal impairment (e GFR <30 m L/min). Chlorthalidone may exacerbate gout and hyperuricemia. Use caution in patients with hepatic impairment or diabetes.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Take this medication exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by your doctor.,Drink plenty of fluids unless otherwise directed by your healthcare provider.,Report symptoms of low blood pressure (dizziness, fainting), electrolyte imbalance (muscle cramps, weakness), or kidney problems (decreased urination).,This drug may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Tell your doctor if you are pregnant or planning to become pregnant; this drug can cause fetal harm.,Limit alcohol intake as it may worsen side effects.,Do not stop taking this medication abruptly without consulting your doctor.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARBYCLOR vs ATACAND HCT, answered by our medical review team.
EDARBYCLOR is a Angiotensin II Receptor Blocker/Thiazide Diuretic Combination that works by EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.. ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARBYCLOR and ATACAND HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARBYCLOR is: One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.. The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARBYCLOR and ATACAND HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARBYCLOR is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the secon. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.